The US Food and Drug Administration (FDA) has accepted for priority review Seagen’s supplemental New Drug Application (sNDA) seeking accelerated approval for its medicine tukysa (tucatinib) along with trastuzumab to treat colorectal cancer.
NeuroBo Pharmaceuticals has signed a conditional exclusive license agreement with Dong-A ST for the development and commercialisation of the latter’s cardio-metabolic therapies, DA-1241 and DA-1726.
Coave Therapeutics and the Institute of Neurodegenerative Diseases (IMN) of Bordeaux have entered into collaboration for developing gene therapy programmes that target protein degradation in neurodegenerative disorders.
Novome Biotechnologies has raised $43.5m in a Series B financing round to advance its therapeutically engineered microbes’ pipeline.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease in new-borns and infants through immunisation of women during pregnancy.
Bristol Myers Squibb has completed the previously announced acquisition of Turning Point Therapeutics, for a total consideration of $4.1bn in cash.
Senda Biosciences has raised $123m in Series C financing round to advance the development of its programmable medicines’ platform into clinical testing.
Chinese biotechnology firm Epigenic Therapeutics has secured $20m in Series Angel and Pre-A funding to proceed with next-generation gene editing therapy.
TransCode Therapeutics has entered into a strategic alliance with the University of Texas MD Anderson Cancer Center for advancing its RNA therapies for oncology.
BridGene Biosciences has raised $38.5m in Series B financing round for the development of its next generation chemoproteomic platform, Isobaric Mass Tagged Affinity Characterization (IMTAC), as well as oncology drugs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.